

1 Estimating the Per-Application Effectiveness of Chlorhexidine Gluconate and Mupirocin in  
2 Methicillin-resistant *Staphylococcus aureus* Decolonization in Intensive Care Units

3  
4 Eric T. Lofgren PhD<sup>1</sup>, Matthew Mietchen MPH<sup>1</sup>, Christopher Short PhD<sup>1</sup>, Kristen V. Dicks<sup>2</sup>,  
5 Rebekah Moehring MD<sup>2</sup>, Deverick Anderson MD<sup>2</sup> for the CDC MIND-Healthcare Program

6  
7 <sup>1</sup> Paul G. Allen School for Global Animal Health, Washington State University, Pullman, WA

8 <sup>2</sup> Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, NC

9  
10 Eric T. Lofgren

11 Paul G. Allen School for Global Animal Health

12 Washington State University

13 240 SE Ott Road, Room 311

14 Pullman, WA 99164-7090

15

16 Email: [Eric.Lofgren@wsu.edu](mailto:Eric.Lofgren@wsu.edu)

17 Phone: (509) 335-4022

18 Fax: (509) 335-6328

19

20 Abbreviated Title: Estimating Per-Application Effectiveness of Chlorhexidine

21

22

23

24

25

26 **Abstract**

27 Introduction: Chlorhexidine gluconate and mupirocin are widely used to decolonize patients  
28 with methicillin-resistant *Staphylococcus aureus* (MRSA) and reduce risks of infection in  
29 hospitalized populations. The probability that a treated patient would be decolonized, which  
30 we term per-application effectiveness, is difficult to directly measure. Quantifying the efficacy  
31 of per-application effectiveness of CHG and mupirocin is important for studies evaluating  
32 alternative decolonization strategies or schedules as well as identifying whether there is room  
33 for improved decolonizing agents.

34  
35 Methods: Using a stochastic compartmental model of an intensive care unit (ICU), the per-  
36 application effectiveness of chlorhexidine and mupirocin were estimated using approximate  
37 Bayesian computation. Extended sensitivity analysis examined the potential impact of a latent  
38 period between MRSA colonization and detection, the timing of decolonization administration,  
39 and parameter uncertainty.

40  
41 Results: The estimated per-application effectiveness of chlorhexidine was 0.15 (95% Credible  
42 Interval: 0.01, 0.42), while the estimated effectiveness of mupirocin was 0.15 (95% CI: 0.01,  
43 0.54). A lag in colonization detection markedly reduced both estimates, which were particularly  
44 sensitive to the value to the modeled contact rate between nurses and patients. Gaps longer  
45 than 24-hours in the administration of decolonizing agents still resulted in substantial reduction  
46 of within-ICU MRSA transmission.

47  
48 Discussion: The per-application effectiveness estimates for chlorhexidine and mupirocin suggest  
49 there is room for substantial improvement in anti-MRSA disinfectants, either in the compounds  
50 themselves, or in their delivery mechanism. Despite these estimates, these agents are robust to  
51 delays in administration, which may help in alleviating concerns over patient comfort or  
52 toxicity.

53

54

## 55 Introduction

56           Despite recent progress in reducing the incidence of methicillin-resistant *Staphylococcus*  
57 *aureus* (MRSA) in hospitals<sup>1</sup>, it remains a targeted pathogen for infection prevention and public  
58 health efforts. One intervention with increasingly widespread use is decolonization of patients  
59 with MRSA using chlorhexidine gluconate (CHG) baths for the skin and mupirocin for the nares.  
60 While these interventions have shown to be effective in a number of randomized controlled  
61 trials<sup>2</sup>, the results from some community-based studies have been more equivocal<sup>3</sup>. There are  
62 several possible explanations for this discrepancy. The results from the randomized trials may  
63 not generalize well to settings with lower MRSA incidence. Similarly, lower-incidence settings  
64 may not be sufficiently powered to detect an effect of implementing decolonization programs.  
65 Finally, there may be changes in implementation from the trial setting to everyday use that  
66 decreases the overall effect of the intervention. Thus, infection prevention programs  
67 considering these strategies in lower incidence settings must justify the cost of the  
68 decolonization products and implementation effort in their hospitals. A better understanding of  
69 effectiveness on the per patient application level may help weigh the implementation costs of  
70 these interventions.

71           Evaluating these discrepancies requires a mechanistic understanding of the  
72 effectiveness of decolonization – that is, what is the probability, if a patient is treated with a  
73 decolonization agent, that they are indeed decolonized? This estimate is essential for a number  
74 of potential uses: cost-effectiveness studies, quantifying the impact of a decolonization  
75 protocol in conjunction with other interventions, or studying the future impact of changes in  
76 effectiveness, due to new technology, emerging resistance to decolonizing agents, or other  
77 factors. Obtaining such an estimate empirically, especially in a community setting, would be  
78 difficult, requiring intensive and repeated sampling of patients with already complicated clinical  
79 cases. Rather than directly measuring the probability of successful decolonization, a  
80 mathematical modeling approach can define what probability best supports the results seen in  
81 the clinical trials – and with what degree of certainty.

82           The aim of this mathematical modeling study was to estimate the per-application  
83 effectiveness of both CHG bathing and CHG bathing in conjunction with mupirocin  
84 decolonization of the nares.

85

## 86 **Methods**

### 87 *MRSA Transmission Model*

88           We adapted a previously published stochastic compartmental model<sup>4,5</sup> of transmission  
89 of MRSA through an ICU. The model included compartments for patient colonization status and  
90 the presence or absence of contamination on the hands or clothing of healthcare workers  
91 (HCWs). Patients were modeled as being either presently uncolonized ( $P_U$ ) or colonized ( $P_C$ ).  
92 were modeled as being either presently uncolonized ( $P_U$ ) or colonized ( $P_C$ ), while HCWs were  
93 modeled as being either uncontaminated ( $S_U$ ) or contaminated ( $S_C$ ). The model assumed that  
94 transmission occurred when a contaminated HCW came into contact with an uncolonized  
95 patient, and contamination occurred when an uncontaminated HCW came into contact with a  
96 colonized patient (Figure 1). As there is considerable evidence that MRSA can be spread via  
97 surface-contamination as well as direct contact<sup>6</sup>, we modeled contact between a patient and an  
98 HCW as a direct care task<sup>7,8</sup> involving either interaction with a patient or their immediate  
99 surroundings.

100           We simulated an 18-bed closed ICU assumed to be at maximum capacity, with a 1:3  
101 nurse:patient ratio and a single dedicated intensivist. Because an intensive care unit is a highly  
102 structured population, this model relaxes the random mixing assumption used in many  
103 compartmental models, instead sub-dividing the patient population such that each patient is  
104 cared for by a single nurse and that nurse exclusively cares for three patients. While this is a  
105 simplification of the structure of an ICU, previous work has shown it to be a more conservative  
106 assumption when compared to random mixing<sup>4</sup>. The intensivist was assumed to treat all  
107 patients (Figure 2).

108           This model makes several simplifying assumptions intended to largely mimic the  
109 environment of a hospital with no major outstanding failings in their infection control program.  
110 Patients were assumed to be homogeneous in their risk of MRSA acquisition, and the contact

111 frequency between HCWs and patients, while non-random, was uniform (i.e. there are no  
112 particularly difficult or contact-intensive patients). Patients were assumed to not interact with  
113 each other directly and to be assigned to single-occupancy rooms. Hospitals were assumed to  
114 follow standard contact precaution guidelines set forward by the CDC and to detect MRSA  
115 colonization with perfect accuracy. Finally, all HCWs were assumed to wash their hands after  
116 each direct care task and to change their gloves and/or gowns at a rate equal to when entering  
117 and exiting the patient room. These assumptions are intended to largely mimic the  
118 environment of a hospital with no major outstanding failings in their infection control program.

119

### 120 *Parameterization and Model Calibration*

121 The model largely used parameter values from a previously published model<sup>4,5</sup>. The  
122 values of each parameter in the model, and the source they were drawn from, are detailed in  
123 Table 1. The stochastic reaction equations that govern the model and code necessary to run the  
124 simulations are available at [https://github.com/epimodels/chg\\_effectiveness](https://github.com/epimodels/chg_effectiveness). The transition  
125 terms are provided in Supplemental Appendix A. Where possible, parameters were drawn from  
126 studies from large academic medical centers similar to the ones conducting large RCTs on  
127 decolonization protocols.

128

### 129 *Decolonization Intervention Efficacy Estimation*

130 In order to estimate the per-application effectiveness of a CHG and/or a CHG-Mupirocin  
131 combination intervention, we used a three-step fitting procedure: baseline, intervention 1 (CHG  
132 baths), and intervention 2 (CHG baths plus nasal mupirocin). First, a baseline model of a pre-  
133 intervention intensive care unit was fit using a single free parameter,  $\psi$ , that governs the  
134 probability an uncolonized patient becomes colonized after contact with contaminated  
135 healthcare worker. This parameter was tuned such that the model had an average incidence of  
136 5.89 MRSA acquisitions per 1000 patient-days<sup>5,9</sup>. Second, we introduced a new parameter,  $\delta$ , to  
137 represent CHG-based decolonization, when a patient moved patients from a colonized status to  
138 an uncolonized status (Intervention 1). This parameter was assumed to result in a 0.748  
139 incidence rate ratio compared to the baseline model, in line with a meta-analysis of CHG-only

140 studies by Kim *et al*<sup>2</sup>. Third, a second parameter which moved patients from colonized to  
141 uncolonized,  $\zeta$ , was fit to represent the addition of nasal decolonization with mupirocin  
142 accompanying a CHG bathing protocol (Intervention 2), resulting in a combined incident rate  
143 ratio of 0.578. This formulation assumes that the effects of CHG and mupirocin are additive and  
144 that there is no synergistic effect between them.

145 Approximate Bayesian Computation (ABC) was used to fit these parameters. Details on  
146 ABC for model fitting may be found elsewhere<sup>10,11</sup>. Briefly, ABC is a computational technique  
147 that draws a candidate value from a prior distribution, simulates the model using that value,  
148 and accepts the candidate value if the simulated result is within an error band around a given  
149 summary statistic. In this case, we fit the model to incidence rates corresponding to the  
150 baseline and the two simulated interventions. The distribution of these accepted values is an  
151 approximation of a Bayesian posterior. In this study, all parameters were fit using 1,000,000  
152 parameter draws from a uniform prior distribution bounded by 0.0 and 1.0. Candidate  
153 parameters were accepted with an error term,  $\varepsilon = 0.05$ , indicating that the simulated incidence  
154 rates had to be within  $\pm 5\%$  of the target incidence rate on the log scale.

155

### 156 *Sensitivity Analysis*

157 Three separate sensitivity analyses were conducted. The first varied the frequency with  
158 which decolonization was applied, comparing a baseline of no decolonization to applications of  
159 CHG and mupirocin every 24, 48, 72, 96, and 120 hours to see if a substantial portion of the  
160 modeled efficacy is dependent on the typical schedule of a daily CHG bath.

161 The second was a global sensitivity analysis, simultaneously allowing each parameter to  
162 vary uniformly  $\pm 50\%$  of its original value. For each parameter draw, 200 model runs were  
163 performed and the joint efficacy of CHG and mupirocin (as a single parameter) was re-  
164 estimated. This process was repeated 5,000 times, and linear regression was used to estimate  
165 the relative impact of a single percentage change in each parameter value on the estimated  
166 efficacy.

167 Finally, we conducted a structural sensitivity analysis examining the impact of assuming  
168 – as our model did – that there is no latent period in MRSA colonization, wherein a patient is

169 colonized at sub-detectable levels. We added a latent period to our model, wherein patients  
170 transitioned from  $P_s$  to a new compartment,  $P_E$ —representing latent colonization—before finally  
171 transitioning to the  $P_c$  colonized state. The rate of transition from  $P_E$  to  $P_c$  varied randomly from  
172 one to four days<sup>12</sup>. Patients in  $P_E$  were assumed not to shed sufficient amounts of MRSA to  
173 contaminate healthcare workers. Effectively, this creates a small pool of patients who, despite  
174 being decolonized due to treatment, are not recognized as such, as their MRSA acquisition has  
175 not yet been detected. The per-application efficacy of CHG and mupirocin were then re-  
176 estimated using the same procedures as the main model.

177

## 178 **Results**

### 179 *Per-Application Efficacy of CHG Bathing and CHG-Mupirocin Combinations*

180 The estimated per-application efficacy of CHG bathing to induce colonization rates  
181 similar to those seen in Kim *et al.* was 0.15 (95% Credible Interval (CI): 0.01, 0.42), meaning a  
182 little under a sixth of all applications of CHG are expected to result in effective decolonization of  
183 the patient. Mupirocin had an estimated per-application effectiveness of 0.15 (95% CI: 0.01,  
184 0.54). The posterior densities of the efficacy estimates are shown in Figure 3. The addition of a  
185 1 to 4-day latent period in between the transmission event and recognized MRSA colonization  
186 reduced both efficacy estimates. In this case, CHG and Mupirocin had estimated per-application  
187 efficacies of 0.11 (95% CI: 0.01, 0.30) and 0.10 (0.004, 0.34) respectively (Figure 3).

188

### 189 *Model Sensitivity to Variation in Timing and Parameter Uncertainty*

190 Despite this relatively modest per-application efficacy estimate, the results of the timing  
191 sensitivity analysis showed that substantial decreases in MRSA acquisitions can be achieved at  
192 much less frequent bathing intervals. Compared to a mean of 1.23 acquisitions per 1,000  
193 patient-days in the control scenarios, a bathing protocol administering CHG and mupirocin  
194 every 120 hours (5 days) resulted in a mean acquisition rate of 1.03 acquisitions per 1,000  
195 patient days, a 16.3% decrease ( $p > 0.001$ ) (Figure 4).

196 The model's results were most sensitive to the value of  $\rho_N$ , the contact rate between  
197 nurses and patients. A 1% increase in the value of this parameter corresponded to a 0.73%

198 increase in the estimated combined efficacy of CHG and mupirocin (95% CI: 0.71, 0.75). Other  
199 sensitive parameters included  $\psi$ , the probability of colonization given contact between a  
200 contaminated HCW and a patient (0.43% (95% CI: 0.41, 0.44) and  $\nu$ , the proportion of  
201 admissions colonized with MRSA (0.37% (95% CI: 0.35, 0.39). The sensitivity estimates for all  
202 varied parameters is shown in Figure 5.

203

## 204 **Discussion**

205 Using a mathematical model to translate from population-level effect estimates to a  
206 per-application effectiveness estimate, this study suggests that on a per-application basis both  
207 CHG and mupirocin are at best mildly effective at decolonizing patients with MRSA. Under ideal  
208 circumstances, the combination of the two compounds was estimated to be effective 30% of  
209 the time. Under more realistic circumstances where there is some delay and uncertainty  
210 between the acquisition and detection of MRSA, either due to biological processes surrounding  
211 colonization or laboratory testing, this estimate drops dramatically to 20%.

212 These results should not be taken as a condemnation of the utility of CHG as an option  
213 for reducing the transmission of MRSA within hospitals. Rather, it illustrates that even relatively  
214 imperfect interventions may still have impact. Further, it suggests that there may be room for  
215 substantial further gains by improving the methods by which we decolonize patients.  
216 Importantly, this model cannot distinguish whether or not the effectiveness of CHG and  
217 mupirocin are due to the compounds themselves or the way in which they are applied. This  
218 means that, even in the absence of novel compounds, improvements to the methods of  
219 applying CHG and mupirocin may reap considerable benefits<sup>13,14</sup>.

220 The results of the timing-focused sensitivity analysis show that considerable deviations  
221 from an intensive 24-hour decolonization schedule can still result in substantial reductions in  
222 the unit-level MRSA acquisition rate. Most healthcare-associated pathogens have relatively low  
223 transmissibility<sup>15-17</sup>, and as such any reduction in the colonization pressure within an ICU, even  
224 a modest one, can interrupt delicate transmission chains. This study suggests that deviations  
225 from a daily CHG bathing schedule due to concerns over toxicity in pediatric populations,  
226 patient-reported skin irritation, or other practical demands are still potentially useful



227 interventions. These results are also potentially useful for future studies, allowing facilities to  
228 estimate the expected impact in their specific settings, allowing for the critical evaluation of  
229 existing studies, and providing clear estimates that can be used to estimate the impact of  
230 resistance to CHG, mupirocin, or both.

231         This study is not without limitations. Broadly, it assumes that the ICU represented in the  
232 model, which is meant to represent the type of academic medical center where large-scale  
233 intervention trials are most often conducted, is a reasonable representation of the environment  
234 in which the studies were actually conducted. The parameter sensitivity analysis shows that the  
235 model is most sensitive to errors in the contact rate between nurses and patients. Further, like  
236 the meta-analysis by Kim *et al.* that was used to calibrate the model and estimate the per-  
237 application effectiveness of CHG and mupirocin, this study assumes that the studies in question,  
238 a mix of randomized trials and interrupted time-series studies, were capable of estimating the  
239 population-level impact of decolonization without bias. Additionally, this model assumes there  
240 is no cumulative benefits to repeated bathing – each application is treated as a separate and  
241 independent event.

242         Despite these limitations, this study represents an innovative use of mathematical  
243 modeling to estimate the effectiveness of a hospital epidemiology intervention using summary  
244 statistics to estimate an individual-level effect. In particular, estimating the per-application  
245 efficacy of these compounds would be difficult, if not impossible, to directly measure in a  
246 working healthcare setting. It shows that there are still substantial prospects for improved  
247 decolonization interventions to further reduce MRSA rates in the ICU, and that there is room  
248 for deviation from intensive daily protocols in response to patient or clinician needs without  
249 overly jeopardizing their impact.

250

## 251 **Acknowledgements**

252 This work was supported by the CDC Cooperative Agreement RFA-CK-17-001-Modeling  
253 Infectious Diseases in Healthcare Program (MInD-Healthcare). We thank the members of the  
254 MInD-Healthcare network for their advice and input.

255

256


257 **References**

- 258 1. Kourtis AP, Hatfield K, Baggs J, et al. Vital signs: Epidemiology and recent trends in  
259 methicillin-resistant and in methicillin-susceptible staphylococcus aureus bloodstream  
260 infections - United States. *Morb Mortal Wkly Rep*. 2019. doi:10.15585/mmwr.mm6809e1
- 261 2. Kim HY, Lee WK, Na S, Roh YH, Shin CS, Kim J. The effects of chlorhexidine gluconate  
262 bathing on health care-associated infection in intensive care units: A meta-analysis. *J Crit*  
263 *Care*. 2016. doi:10.1016/j.jcrc.2015.11.011
- 264 3. Dicks K V, Lofgren E, Lewis SS, Moehring RW, Sexton DJ, Anderson DJ. A Multicenter  
265 Pragmatic Interrupted Time Series Analysis of Chlorhexidine Gluconate Bathing in  
266 Community Hospital Intensive Care Units. *Infect Control Hosp Epidemiol*. February  
267 2016:1-7. doi:10.1017/ice.2016.23
- 268 4. Mietchen MS, Short CT, Samore M, Lofgren ET. Population Structure Drives Differential  
269 Methicillin-resistant & Staphylococcus aureus Colonization  
270 Dynamics. *medRxiv*. January 2019:19002402. doi:10.1101/19002402
- 271 5. Lofgren ET. Estimating the impact post randomization changes in staff behavior in  
272 infection prevention trials: a mathematical modeling approach. *BMC Infect Dis*.  
273 2017;17(1):539. doi:10.1186/s12879-017-2632-1
- 274 6. Otter JA, Yezli S, Salkeld JAG, French GL. Evidence that contaminated surfaces contribute  
275 to the transmission of hospital pathogens and an overview of strategies to address  
276 contaminated surfaces in hospital settings. *Am J Infect Control*. 2013.  
277 doi:10.1016/j.ajic.2012.12.004
- 278 7. Westbrook JI, Duffield C, Li L, Creswick NJ. How much time do nurses have for patients? A  
279 longitudinal study quantifying hospital nurses' patterns of task time distribution and  
280 interactions with health professionals. *BMC Health Serv Res*. 2011;11:319.  
281 doi:10.1186/1472-6963-11-319
- 282 8. Ballermann MA, Shaw NT, Mayes DC, Gibney RTN, Westbrook JI. Validation of the Work  
283 Observation Method By Activity Timing (WOMBAT) method of conducting time-motion  
284 observations in critical care settings: an observational study. *BMC Med Inform Decis Mak*.  
285 2011;11:32. doi:10.1186/1472-6947-11-32

- 286 9. Harris AD, Pineles L, Belton B, et al. Universal glove and gown use and acquisition of  
287 antibiotic-resistant bacteria in the ICU: a randomized trial. *JAMA*. 2013;310(15):1571-  
288 1580. doi:10.1001/jama.2013.277815
- 289 10. Tanaka MM, Francis AR, Luciani F, Sisson SA. Using approximate Bayesian computation to  
290 estimate tuberculosis transmission parameters from genotype data. *Genetics*. 2006.  
291 <http://www.genetics.org/content/173/3/1511.short>.
- 292 11. Sunnåker M, Busetto AG, Numminen E. Approximate bayesian computation. *PLoS*  
293 *Comput ....* 2013.  
294 <http://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1002803>.
- 295 12. Dancer SJ, Coyne M, Speekenbrink A, Samavedam S, Kennedy J, Wallace PGM. MRSA  
296 acquisition in an intensive care unit. *Am J Infect Control*. 2006.  
297 doi:10.1016/j.ajic.2005.08.009
- 298 13. Rhee Y, Palmer LJ, Okamoto K, et al. Differential Effects of Chlorhexidine Skin Cleansing  
299 Methods on Residual Chlorhexidine Skin Concentrations and Bacterial Recovery. *Infect*  
300 *Control Hosp Epidemiol*. 2018. doi:10.1017/ice.2017.312
- 301 14. Ryder M. Evaluation of Chlorhexidine Gluconate (CHG) Delivered to the Skin Following  
302 Standard Pre-Op Prepping Protocols of 4% CHG Solution Versus No-Rinse 2% CHG Cloth.  
303 *Am J Infect Control*. 2007. doi:10.1016/j.ajic.2007.04.016
- 304 15. Cooper BS, Medley GF, Stone SP, et al. Methicillin-resistant *Staphylococcus aureus* in  
305 hospitals and the community: Stealth dynamics and control catastrophes. *Proc Natl Acad*  
306 *Sci U S A*. 2004. doi:10.1073/pnas.0401324101
- 307 16. Prosperi M, Veras N, Azarian T, et al. Molecular epidemiology of community-associated  
308 Methicillin-resistant *Staphylococcus aureus* in the genomic era: A cross-sectional study.  
309 *Sci Rep*. 2013. doi:10.1038/srep01902
- 310 17. Batina NG, Crnich CJ, Anderson DF, Döpfer D. Identifying conditions for elimination and  
311 epidemic potential of methicillin-resistant *Staphylococcus aureus* in nursing homes.  
312 *Antimicrob Resist Infect Control*. 2016. doi:10.1186/s13756-016-0130-7
- 313 18. Lofgren ET, Moehring RW, Anderson DJ, Weber DJ, Fefferman NH. A Mathematical  
314 Model to Evaluate the Routine Use of Fecal Microbiota Transplantation to Prevent

- 315 Incident and Recurrent Clostridium difficile Infection. *Infect Control Hosp Epidemiol.*  
316 2014;35(1):18-27. doi:10.1086/674394
- 317 19. Austin DJ, Anderson RM. Studies of antibiotic resistance within the patient, hospitals and  
318 the community using simple mathematical models. *Philos Trans R Soc Lond B Biol Sci.*  
319 1999;354(1384):721-738. doi:10.1098/rstb.1999.0425
- 320 20. Sickbert-Bennett EE, Weber DJ. Comparative efficacy of hand hygiene agents in the  
321 reduction of bacteria and viruses. *Am J ...* 2005.  
322 <http://www.sciencedirect.com/science/article/pii/S0196655304005875>.
- 323 21. Khader K, Thomas A, Huskins WC, et al. A dynamic transmission model to evaluate the  
324 effectiveness of infection control strategies. *Open Forum Infect Dis.* 2017.  
325 doi:10.1093/ofid/ofw247
- 326
- 327

328



329

330

331

332


333

334


335

336


**Figure 1.** Schematic representation of the compartmental flow of a mathematical model of methicillin-resistant *Staphylococcus aureus* (MRSA) acquisition and CHG/mupirocin decolonization. Solid arrows indicate possible transition states, while dashed arrows indicate potential routes of MRSA contamination or colonization. Nurses and doctors are classified as uncontaminated (NU or DU) and contaminated (NC and DC), while patients are classified as uncolonized (PU) or colonized (PC). Figure by Eric Lofgren is licensed under CC BY 4.0.



337  
338 **Figure 2.** Schematic representation of a structured intensive care unit population to model  
339 methicillin-resistant *Staphylococcus aureus* (MRSA) acquisition and CHG/mupirocin  
340 decolonization. Patients (blue) are treated by a single assigned nurse (orange). A single  
341 intensivist (red) randomly treats all patients. Figure by Eric Lofgren is licensed under CC BY 4.0.  
342




343  
344 **Figure 3.** Approximate Bayesian Posterior Estimates for Per-Application Chlorhexidine  
345 Gluconate ( $\delta$ ) and Mupirocin ( $\zeta$ ) Effectiveness. Each panel shows the density of accepted  
346 values (dark line) and the median of this density (dotted line). Densities were estimated using a  
347 normal kernel. Left-hand panels show the estimates assuming acquisition is instantly detected,  
348 while the right-hand panels show the estimates assuming there is a one to four-day latent  
349 period where a patient may be colonized (and decolonized) but their acquisition is not yet  
350 detected.  
351



352  
353 **Figure 4.** Violin plot of the Sensitivity of Decolonization Protocols to Changes in Timing. Each  
354 'violin' shows a smoothed kernel-density estimate of 1,000 runs of the model with a given  
355 timing for the administration of decolonizing baths, in acquisitions per 1,000 patient-days.  
356 Solid, black, horizontal bars indicate the mean estimate for each scenario.  
357





358

359 **Figure 5.** Global sensitivity of a mathematical model of methicillin-resistant *Staphylococcus*  
360 *aureus* (MRSA) acquisition and CHG/mupirocin decolonization. Horizontal bars represent the  
361 change in the estimated effectiveness of CHG/mupirocin decolonization per one-percent  
362 change in the value of a specific parameter, with light bars indicating increased estimated  
363 effectiveness and dark bars indicating decreased estimated effectiveness.

364

365 **Table 1.**

Parameter	Parameter Description	Parameter Value	Source(s)
$\rho$	Contact rate between patients and HCWs	4.154 (# of direct care tasks/hour)	7,18
$\rho_N$	Contact rate between patients and nurses	3.973 (# of nurse direct care tasks/hour)	7,18
$\rho_D$	Contact rate between patients and physician	0.181 (# of physician direct care tasks/hour)	7,18
$\sigma$	Probability that a HCW's hands are contaminated from a single contact with a colonized patient	0.054	19
$\psi$	Probability of successful colonization of an uncolonized patient due to contact with a contaminated HCW in metapopulation structure	0.4481	Fitted to 9
$\theta$	Probability of discharge	4.39 days <sup>-1</sup>	9
$v_u$	Proportion of admissions uncolonized with MRSA	0.9221	9
$v_c$	Proportion of admissions colonized with MRSA	0.0779	9
$\iota$	Effective hand-decontaminations/hour (direct care tasks × hand hygiene compliance × efficacy)	5.740 (10.682 direct care tasks/hour × 56.55% compliance × ~ 95% efficacy)	7,9,18,20
$\iota_N$	Effective nurse hand-decontaminations/hour	6.404 (11.92 direct care tasks/hour × 56.55% compliance × ~ 95% efficacy)	7,9,18,20
$\iota_D$	Effective physician hand-decontaminations/hour	1.748 (3.253 direct care tasks/hour × 56.55% compliance × ~ 95% efficacy)	7,9,18,20
$\tau$	Effective gown or glove changes/hour (2 × # of visits × compliance)	2.445 (2.957 changes/hour × 82.66% compliance)	8,9,19
$\tau_N$	Effective nurse gown or glove changes/hour	2.728 (3.30 changes/hour × 82.66% compliance)	8,9,19
$\tau_D$	Effective physician gown or glove changes/hour	0.744 (0.90 changes/hour × 82.66% compliance)	8,9,19
$\mu$	Natural decolonization rate	20.0 days <sup>-1</sup>	21
$\delta$	Per-application Effectiveness of CHG	Estimated	
$\zeta$	Per-application Effectiveness of CHG + Mupirocin	Estimated	
$\eta$	Decolonization application frequency	24.0 hours <sup>-1</sup>	